2025 Plenary Keynote Sessions
MONDAY, August 18, 2025 | 4:20 – 5:30 PM
Increasing mAb Output Ten-Fold while Reducing Natural Resources through Digitalization and New Technologies
Lisbet Jensen Young, Vice President & General Manager, AstraZeneca
This presentation will give insights into the latest sustainability strategies at AstraZeneca and the unique opportunities they provide the leadership of a mAb drug substance manufacturing center, increasing output ten-fold. It will take you through the approaches using digital in the value stream, partnering with suppliers in capacity expansions, and deployment of new technologies.
One-on-One Interview, with Audience Q&A
Lisbet Jensen Young, Vice President & General Manager, AstraZeneca
Interviewed By:
Raghavan V. Venkat, PhD, Senior Vice President, Biopharmaceutical Development, AstraZeneca
WEDNESDAY, August 20, 2025 | 3:50 – 5:00 PM
Fireside Chat: Innovation and Investment in Biomanufacturing of Future Medicine
PANEL MODERATOR:
Ran Zheng, CEO, Landmark Bio
What are the technologies and innovations shaping the future of biomanufacturing in 2025 and beyond? Join us for an engaging plenary panel discussion on "Innovation and Investment in Biomanufacturing of Future Medicine," where leading experts from the investment and strategies community will explore upcoming trends, investment opportunities, and modalities into the next decade. How should the industry best prepare?
PANELISTS:
David Y. H. Chang, CEO, Taiwan Bio-Manufacturing Company (TBMC)
Bo Wiinberg, PhD, Chief Business Development Officer, Novo Nordisk Foundation Cellerator
Paul Lewus, PhD, Vice President, Site Operations, Amgen Inc.
Plenary Speaker Biographies
Lisbet Jensen Young, Vice President & General Manager, AstraZeneca
Lisbet is the Vice President and General Manager for AstraZeneca’s Biologics manufacturing center in Frederick, Maryland where she leads a workforce of 750 people who make life-changing medicines for patients around the world. Living and working in five countries before moving to Frederick, coupled with her background in chemical engineering, prepared Lisbet for various roles of increasing responsibilities within manufacturing, quality assurance, supply chain and validation. She has a strong focus on diversity and inclusion, and a passion for ensuring robust career development opportunities for her teams and advancing sustainability results.
Ran Zheng, CEO, Landmark Bio
Ms. Zheng is a biotechnology industry veteran who brings more than 25 years of experience in biotechnology operations across multiple geographies to Landmark Bio. Ms. Zheng most recently served as Chief Technical Officer at Orchard Therapeutics, a commercial-stage global gene therapy company specializing in HSC based gene therapies. In this role, Ms. Zheng established the technical operations function and manufacturing network, and advanced the company’s product pipeline, including the approval of Libmeldy™ – the first gene therapy product for metachromatic leukodystrophy. Ms. Zheng has also held leadership positions at several major biotechnology companies including Genzyme (now Sanofi) and Amgen. At Amgen, Ms. Zheng played a key role in building differentiating capabilities in manufacturing for clinical supply and commercial product launch to enable speed to clinic and speed to market strategies for Amgen’s innovative products.
David Y. H. Chang, CEO, Taiwan Bio-Manufacturing Company (TBMC)
Dr. David Chang has 30-year industrial experience, and is currently the CEO of TBMC (Taiwan Bio-Manufacturing Co), Taiwan. Prior to current role, he was CEO of Wuxi AppTec Advanced Therapies Business Unit located in Philadelphia, PA.; Corporate VP and Head of Cell Therapy Global Manufacturing, of Celgene Corporation; the Global Head of Engineering and Strategy at Roche based in Basel, Switzerland; the VP/Site Head of Roche Shanghai Technical Operations in China. Earlier in his career, Dr. David Chang worked at Genentech as the Senior Director of Global Manufacturing Science and Technology, and as the Director of Process Development in its Oceanside, CA site. He was also formerly at Biogen Idec as Director of cell culture R&D, at BASF Bioresearch as a cell culture group leader, and at Schering-Plough Research Institute as a process development engineer. Dr. David Chang obtained his Bachelor’s degree in Chemical Engineering from National Taiwan University in Taiwan, and the Master’s and PhD degrees in Biochemical Engineering from MIT in Massachusetts, USA.
Bo Wiinberg, PhD, Chief Business Development Officer, Novo Nordisk Foundation Cellerator
Bo is a seasoned leader with extensive experience from both academia, the pharmaceutical and biotech sectors, focusing on strategic and operational leadership throughout the drug development value chain. Bo was previously an Entrepreneur in Residence at the BioInnovation Institute and at Novo Nordisk A/S, Bo held several leadership positions over the years, including Head of Strategy & Operations for the Stem Cell unit. Bo is a Doctor of Veterinary Medicine, earned a PhD from the University of Copenhagen and has numerous publications in peer-reviewed journals.
Paul Lewus, PhD, Vice President, Site Operations, Amgen Inc
Paul Lewus is the head of site operations for Amgen’s new advanced drug substance manufacturing site in Holly Springs, North Carolina. He has over 20 years of biotechnology industry experience leading Process Development, Manufacturing, and Quality functions. He is passionate about hiring and developing the best talent, deploying innovative manufacturing technologies, and commercializing new medicines for the benefit of patients. He has a B.S. in Chemical Engineering from Colorado State University and a Ph.D. in Chemical Engineering from the University of Virginia.